Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 355 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control Vaccine 4 Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

NCT07049159
View directory record Official record
Conditions
Shigella
Interventions
ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU
Biological · Other
Lead sponsor
Eveliqure Biotechnologies GmbH
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 1, 2026, 10:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Motivational Interviewing and Vaccine Hesitancy in Children

NCT03934008
View directory record Official record
Conditions
Vaccine Hesitancy
Interventions
MOtivational interviewing Tool to Improve Vaccine AdherencE (MOTIVE)
Other
Lead sponsor
Cedarville University
Other
Eligibility
0 Years to 6 Years
Enrollment
4,191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Springfield, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

NCT04451954
View directory record Official record
Conditions
Influenza Immunisation, Healthy Volunteers
Interventions
Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 2 and adjuvant, Quadrivalent RIV with 2018-2019 NH H3 strain, Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 1, 2026, 10:42 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06736041
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,714 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
66
States / cities
Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

NCT02431312
View directory record Official record
Conditions
Hepatitis B
Interventions
INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment
Biological · Drug
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Manhasset, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Results available

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

NCT03934736
View directory record Official record
Conditions
End Stage Renal Disease on Hemodialysis (Diagnosis)
Interventions
HEPLISAV-B®
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

NCT01364571
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, Blood sample, SA4Ag vaccine high dose, Placebo
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
16
States / cities
Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

NCT02473510
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 1, 2026, 10:42 AM EDT
Active, not recruiting Phase 2 Interventional

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

NCT04114825
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
RV001V, Placebo
Biological · Other
Lead sponsor
RhoVac APS
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Clearwater, Florida • Towson, Maryland • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

NCT04529538
View directory record Official record
Conditions
Poliomyelitis
Interventions
Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1), Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • Lebanon, New Hampshire • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

NCT01164514
View directory record Official record
Conditions
Bacterial Sepsis
Interventions
CPG 7909, J5-OMP Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

NCT03014310
View directory record Official record
Conditions
Avian Influenza
Interventions
AS03, MF59, Monovalent Influenza A/H5N8 vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
7
States / cities
Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

NCT04626297
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
85
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • North Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

NCT03473002
View directory record Official record
Conditions
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions
Placebo, SeVRSV Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HPV Message Testing and Social Media Campaign

NCT03747302
View directory record Official record
Conditions
Vaccine, Human Papilloma Virus
Interventions
Social Media Message about HPV and HPV vaccine, Social media message about risk of electronic cigarettes.
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
1,043 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age

NCT01857206
View directory record Official record
Conditions
Influenza, Fever
Interventions
Mammalian cell based flu vaccine, Egg based flu vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
4 Years to 17 Years
Enrollment
2,055 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
18
States / cities
Mobile, Alabama • Ponte Vedra, Florida • Augusta, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

NCT03731182
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Wilmington, Delaware • Atlanta, Georgia • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Hepatitis E Vaccine (HEV239)

NCT03827395
View directory record Official record
Conditions
Hepatitis E, Immunisation
Interventions
HEV 239, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria

NCT01169077
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Placebo, EP-1300
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Sep 1, 2026, 10:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Influenza Vaccine in Lung Transplant Patients - Seroprotection

NCT04531657
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants

NCT00444457
View directory record Official record
Conditions
Vaccines, Pneumococcal
Interventions
13-valent Pneumococcal Conjugate Vaccine, 7vPnC
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
1,712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Benton, Arkansas • Conway, Arkansas • Fayetteville, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 1 Interventional

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

NCT00000829
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 1, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

NCT02837575
View directory record Official record
Conditions
Herpes Genitalis
Interventions
VCL-HB01, Phosphate-buffered saline
Biological · Other
Lead sponsor
Vical
Industry
Eligibility
18 Years to 50 Years
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 1, 2026, 10:42 AM EDT